Edition:
United States

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

16.15USD
8 Dec 2017
Change (% chg)

$-0.15 (-0.92%)
Prev Close
$16.30
Open
$16.40
Day's High
$16.55
Day's Low
$15.90
Volume
78,246
Avg. Vol
173,126
52-wk High
$19.10
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Mirati prices public offering of 2 mln shares at $13 per share​
Thursday, 16 Nov 2017 08:45am EST 

Nov 16 (Reuters) - Mirati Therapeutics Inc -:Mirati Therapeutics announces pricing of public offering of common stock.Mirati Therapeutics Inc - ‍pricing of underwritten public offering of 2 million shares of its common stock at a price to public of $13.00 per share​.  Full Article

Mirati announces advancement of opportunities with inhibitor programs
Monday, 13 Nov 2017 04:15pm EST 

Nov 13 (Reuters) - Mirati Therapeutics Inc ::Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs.Mirati Therapeutics - ‍"reprioritizing" development programs to capitalize on data and development opportunities in its sitravatinib and kras programs​.Mirati Therapeutics - ‍reallocation of resources to support expansion of sitravatinib and kras programs, is expected to fund operations into late 2019​.  Full Article

Mirati Therapeutics reports Q3 loss per share of $0.65
Wednesday, 1 Nov 2017 04:30pm EDT 

Nov 1 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.65.Q3 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S.‍Research and development expenses for Q3 of 2017 were $13.5 million, compared to $16.1 million for same period in 2016​.  Full Article

Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients
Thursday, 12 Oct 2017 04:45pm EDT 

Oct 12 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics' mocetinostat included in stand up to cancer's cutting-edge clinical trial initiative for NSCLC patients.  Full Article

Mirati Therapeutics presents positive data from on-going clinical trials of sitravatinib
Thursday, 14 Sep 2017 04:33pm EDT 

Sept 15 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics Inc presents positive preliminary data from on-going clinical trials of sitravatinib in non-small cell lung cancer.Mirati Therapeutics Inc - in both clinical studies, Sitravatinib alone and in combination with nivolumab was well tolerated with a manageable safety profile.  Full Article

Mirati Therapeutics reports Q2 loss per share $0.74
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Mirati Therapeutics Inc -:Mirati Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.74.Q2 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S.Mirati Therapeutics - ‍cash, cash equivalents, and short-term investments were $87.8 million at june 30, 2017, compared to $56.7 million at December 31, 2016​.  Full Article

Mirati Therapeutics Q1 loss per share $0.73
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Mirati Therapeutics Inc ::Mirati Therapeutics - expect currently available cash, cash equivalents and short-term investments sufficient to fund operations into late 2018.Mirati Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.73.Q1 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S.  Full Article

Mirati therapeutics reports financial results and provides business update for the fourth quarter and full year 2016
Thursday, 9 Mar 2017 04:05pm EST 

Mirati Therapeutics Inc : Mirati therapeutics - following public offering in january, well positioned to achieve 2017 milestones in each of programs with funding into late 2018 . Mirati therapeutics reports financial results and provides business update for the fourth quarter and full year 2016 . Q4 loss per share $0.99 .Q4 earnings per share view $-0.97 -- Thomson Reuters I/B/E/S.  Full Article

Mirati Therapeutics reports Q3 loss per share $0.97
Thursday, 3 Nov 2016 04:10pm EDT 

Mirati Therapeutics Inc - : Mirati Therapeutics reports financial results and provides business update for the third quarter 2016 . Q3 loss per share $0.97 .Q3 earnings per share view $-1.16 -- Thomson Reuters I/B/E/S.  Full Article

Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics
Wednesday, 10 Aug 2016 03:00pm EDT 

Mirati Therapeutics Inc : Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics as of August 8, 2016 - SEC Filing Source - http://bit.ly/2aMdcIv Further company coverage: [MRTX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Mirati announces advancement of opportunities with inhibitor programs

* Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs